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Intrarenal interleukin-15 (IL-15) plays a major role controlling epithelial survival and polarization both in
physiological and pathologic conditions. Herein, we confirmed that human renal cell carcinomas (RCCs) express
a membrane-bound IL-15 isoform displaying an unusual molecular weight of 27 kDa. Its stimulation with soluble IL-
15 receptor α chain (s-IL-15Rα) triggers epithelial-mesenchymal transition (EMT) process as shown by the down-
regulation of E-cadherin and zona occludens 1 and the up-regulation of vimentin and N-cadherin and promotes the
migratory and invasive properties of RCC. S-IL-15Rα treatment triggered the Src/PI3K/Akt/GSK-3β pathway and
promoted β-catenin nuclei translocation. Deactivation of this pathway by using Src-specific inhibitor PP2, PI3K
inhibitor LY294002, and AKT inhibitor MK2206 hampered β-catenin nuclei translocation and suppressed EMT,
migration, and invasion of RCC. S-IL-15Rα treatment also enhanced Src-dependent phosphorylation of focal
adhesion kinase (FAK) and extracellular signal–regulated kinase (Erk1/2). FAK knockdown significantly decreased
the migration and invasion of RCC, which suggest that Src-FAK signaling was involved in s-IL-15Rα–favored
migration and invasion of RCC. At the same time, inhibitors of Erk1/2 also significantly decreased the migration
and invasion of RCC but could not reverse s-IL-15Rα–induced EMT. Taken together, our results reveal that Src-
dependent PI3K/Akt/GSK3b/β-catenin pathway is required for s-IL-15Ra–dependent induction of EMT in RCC, while
Src-FAK and Src-Erk1/2 signaling were involved in s-IL-15Rα–promoted migration and invasion properties of RCC.
Our study provides a better understanding of IL-15 signaling in RCC tumor progression, which may lead to novel
targeted therapies and provide some suggestions when using IL-15 in clinic.
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Kidney cancer accounts for about 2% of all cancers, and worldwide,
N250,000 new cases of kidney cancer are diagnosed each year. Renal cell
carcinoma (RCC) is the most common form of adult kidney cancer
denoting a diverse set of neoplasias with unique genetic and histologic
feature [1]. The RCCs emanate from the renal tubule, a highly
heterogeneous epithelial structure, and the resulting cancer displays
unique characteristics depending on which cell is malignified [2]. The
tubular epithelium is normally mitotically quiescent but demonstrates a
considerable regenerative capacity upon renal injury [2]. It is therefore
reasonable to propose that altered behavior of factors controlling tubular
epithelium homeostasis may be involved in renal cancer progression and
that a better understanding of the underlying biologic mechanisms could
result in improvements in the prevention and treatment of this disease. In
this context, interleukin-15 (IL-15) that plays an important role in renal
homeostasis in both physiological and pathologic conditions could be an
interesting candidate [3–9].
IL-15 is a pleiotropic cytokine that links in vivo innate and adaptive
immune responses and is characterized by different levels of complexity in
its biology [10,11]. Indeed, IL-15 receptor (IL-15R) consists of a private
α-chain and shares IL-2 receptor β- and γ-chains that are expressed
individually or together to form various functional receptorswith different
affinities and signaling capabilities [12,13].Moreover, different functional
forms of IL-15 exist: 1) the soluble form that is secreted at very low
concentration can only activate cells expressing high affinity receptor
[10,11]; 2) the hyper-IL-15 is a functional complex formed by the
association of the soluble IL-15 receptor α chain (s-IL-15Rα) with the
soluble cytokine [14]; 3) the membrane-bound isoform can anchor at the
cell membrane through IL-15Rα [membrane-bound IL-15 (mb-IL-15)]
or through a membrane-binding domain located between residues 21 to
41 of the N-terminus in the IL-15 hydrophobic region [transmembrane-
bound IL-15 (tmb-IL-15)]. The latter is the dominant physiological
isoforms of the cytokine competent for specific interaction with bystander
cells [10,15–17]. In addition, the transmembrane isoform (tmb-IL-15)
can also deliver a reverse signaling to the presenting cells by interacting
with its soluble receptor [16,17].
Experiments in IL-15−/− and IL-15Rα−/−mice show that bindingwith
IL-15Rα, intrarenal mb-IL-15 behaves as an epithelial survival factor
[3,4], while acting through the IL-2/15Rγ (CD132), IL-15 preserves
E-cadherin expression and inhibits the epithelial-mesenchymal transition
(EMT) process [10]. By contrast, in renal cancer, loss of IL-2/15Rγ by
epithelial cells defines a tumoral microenvironment where IL-15 can
trigger EMT [18,19].
As for now, the key pathways implicated in the IL-15–dependent
progression of the disease are only partially explored. Our study here
revealed that the tmb-IL-15 expressed in RCC could respond to the
s-IL-15Rα and promote migration and EMT of RCC by stimulating
Src/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/
β-catenin, Src–focal adhesion kinase (FAK), and Src–extracellular
signal–regulated kinase (Erk) signaling cascades. This better cognition
of the mb-IL-15–dependent signals may help to develop novel
targeted therapies and lead to improvement in the treatment of RCC.Materials and Methods
Chemicals and Reagents
Antibodies against IL-15 [monoclonal antibody (mAb) L-20],
antibodies against N-cadherin, vimentin, and zona occludens 1
(ZO-1), protein A/G–agarose beads, control small interfering RNA(siRNA; sc-37007), and FAK-siRNA (sc-29310) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Primary antibodies
against E-cadherin, p-Src, Src, p-Akt, Akt, p-Erk1/2, Erk1/2, p-FAK,
FAK, p-PI3K, PI3K, p-glycogen synthase kinase-3β (GSK-3β),
GSK-3β, β-catenin, p-Smad2, Smad2, p-Smad3, and Smad3 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies were
purchased from Cell Signaling Technology (Beverly, MA). Anti–
IL-15–phycoerythrin (mAb247-PE), anti-mouse IgG, anti-goat IgG,
rhIL-15 Rα/Fc chimera soluble (s-IL-15Rα) chain, and transforming
growth factor–β (TGF-β) were purchased from R&D Systems
(Minneapolis, MN). Src inhibitor PP2, Akt inhibitor MK2206, and
Erk inhibitor PD98059 were purchased from Sigma-Aldrich (St Louis,
MO). HRP-conjugated secondary antibody, Alexa Fluor 488/594–
conjugated secondary antibody, 4',6-diamidino-2-phenylindole
(DAPI), and Lipofectamine 2000 were purchased from Invitrogen
(Carlsbad, CA). All other chemicals were obtained from Sigma-Aldrich.
Cell Culture
The 786-O renal carcinoma cell line was obtained from the Type
Culture Collection of the Chinese Academy of Sciences (Shanghai,
China). The ACHN renal carcinoma cell line was kindly given by Prof.
Bruno Azzarone from France. 786-O cells and ACHN cells were,
respectively, cultured in RPMI-1640 (Gibco, NY, USA) and Dulbecco's
modified Eagle's medium (Gibco) supplemented with 10% FBS (Gibco),
100 U/ml penicillin, and 100 mg/ml streptomycin under a humidified
5% CO2 atmosphere at 37°C in an incubator.
Flow Cytometry Analysis
Membrane expression of IL-15 (mb-IL-15) was revealed by flow
cytometry using the anti–IL-15 phycoerythrin-conjugated mAb
(mAb247-PE). Anti-mouse IgG1 PE was used as control. For each
sample, 10,000 cells were acquired for data analysis using FACSCalibur
and analyzed with CellQuest software (BD Biosciences, San Jose, CA).
Migration and Invasion Assay
Migration and invasion assays were performed in Boyden chambers.
The polycarbonate filters (8-mm pore size; Corning, NY, USA)
pre-coated with Matrigel Matrix (BD Biosciences) were used for
invasion assay, and uncoated filters were used for migration assay. Cells
(3 × 105) in 300ml of medium (containing 0.1% FBS) with or without
100 ng/ml s-IL-15Rαwere seeded in the upper chamber. Then, 600ml
of medium with 10% FBS was added to the lower chamber and served
as a chemotactic agent. After 4-day incubation, for migration, the cells
that migrated and adhered onto the lower chamber were fixed in 4%
paraformaldehyde for 30 minutes, stained with crystal violet, and
counted under an upright microscope (five fields per chamber). For
invasion, the cells in the upper chamber were fixed in 4%
paraformaldehyde for 30minutes. Then, theMatrigel wasmechanically
removed from the filter with a cotton swab. The cells adhering to the
underside of the filter were stained with crystal violet and counted under
an upright microscope (five fields per chamber).
Western Blot
The cells were washed three times with ice-cold phosphate-buffered
saline (PBS) and then lysed in lysis buffer containing 50mMTris-HCl (pH
7.6), 150mMNaCl, 1mMEDTA, 1%NP-40, 0.5%Na-deoxycholate, 5
m g/ml aprotinin, 5 mg/ml leupeptin, and 1 mM phenylmethylsulfonyl
fluoride. Lysates were cleared by centrifugation and denatured by boiling in
Laemmli buffer. Equal amounts of protein samples were loaded per well
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electrophoretically transferred onto polyvinylidene difluoride (PVDF)
membranes (Millipore, MA, USA). Following blocking with 5% non-fat
milk at room temperature for 1 hour, membranes were incubated with
primary antibodies (1:500) at 4°C overnight and then incubated with
HRP-conjugated secondary antibodies (1:5000) for 2 hours at room
temperature. Detection was carried out using a LumiGLO chemilumines-
cent substrate system (KPL, Guildford, United Kingdom).
Immunofluorescence
The cells were cultured on chamber slides, serum starved for 12
hours, and then exposed to s-IL-15Rα for the indicated time. Cells were
washed three times with PBS, fixed with 4% paraformaldehyde for 30
minutes, and permeabilized with 0.3% Triton X-100 for 30 minutes.
After blocking with 3% BSA for 1 hour, cells were incubated with
antibodies against vimentin, ZO-1, and β-catenin (1:50 dilution) at
room temperature for 2 hours. Slides were washed three times with PBS
and incubated with Alexa Fluor 488– or Alexa Fluor 594–conjugated
secondary antibodies (1:200) for 1 hour at room temperature. Nuclei
were stained withDAPI (10mg/ml) for 1minute. Images were acquired
using fluorescence microscopy (BX51TRF; Olympus, Japan).
Immunoprecipitation
Cells were lysed in 1% digitonin cell extraction buffer [1 mM
EDTA, 150 mM NaCl, 20 mM Tris (pH 8.0), and 10% glycerol]
and protease inhibitor cocktail tablets (complete; Roche, Switerland).
For immunoprecipitation, lysates and plasma membrane fraction
were first pre-cleared with the protein A/G and then incubated
overnight at 4°C with 2 μg of antibody against GSK-3β/AKT bound to
protein A/G or anti-goat IgG bound to protein A/G as control. After
washing, the immunocomplexes were boiled for 5 minutes in sodium
dodecyl sulfate sample buffer and analyzed by Western blot.
RNA Interference
RNA interference was performed as per the manufacturer’s protocols.
Briefly, 2 × 105 cells were seeded in six-well plates and allowed to grow to
50% confluence. Then, cells were transfected with siRNA. The cells wereFigure 1. Stimulation of tmb-IL-15 with s-IL-15Rα promoted cellular m
primary RCCs (786-O, ACHN) was detected by flow cytometry (mAb
control (red peaks). (B) The plasma membrane fraction of 786-O cel
subsequently probed with the same L-20 antibody. A single 27 kDa s
detected no band. (C) The number of invasive and migrated cells afte
represent mean ± SEM of five fields. *P b .05 compared with controallowed to grow for another 18 hours before they were collected for the
following experiments.
Statistical Analysis
Data are expressed as mean ± SD. Student’s t test and one-way
analysis of variance test were used for statistical analyses of the data.
All statistical analyses were conducted using GraphPad Prism
Software Version 5.0 (GraphPad Software Inc, La Jolla, CA). Cases
in which P values are b .05 were considered statistically significant.
Results
Stimulation of tmb-IL-15 with s-IL-15Rα Promoted Cellular
Migration and Invasion of RCC
In Figure 1, A and B, flow cytometric and Western blot analyses
revealed that the RCC cell lines 786-O and ACHN express membrane-
bound IL-15 isoform, characterized by an unusual molecular weight
(MW) of 27 kDa (Figure 1B). To examine whether membrane-bound
IL-15 isoform has any functions, we stimulated RCCwith s-IL-15Rα. As
shown in Figure 1C, stimulation of RCC with s-IL-15Rα strongly
enhanced their invasive potential inMatrigel (two-fold increase) and their
migratory property in migration assay (five-fold increase).
S-IL-15Rα Favored EMT of RCC
The role of tmb-IL-15 signaling in cell migration led us to examine if it
has any effect on the process of EMT in RCC. In Figure 2A,
immunofluorescence analysis showed that stimulation of tmb-IL-15 with
100 ng/ml s-IL-15Rα is as efficient as 5 ng/ml TGF-β in inducing the
up-regulation of the mesenchymal marker vimentin and the down-regu-
lation of the epithelialmarker ZO-1. Interestingly, analysis of themagnified
inset showed that untreated RCC displayed epithelial morphology and a
very scant expression of vimentin, while s-IL-15Rα treatment induced a
fibroblast-like morphology with a strong expression of a network of
vimentin filaments. In Figure 2B, Western blot analysis confirmed that
s-IL-15Rα efficiently induced the down-regulation of epithelial markers
(ZO-1 and E-cadherin) and the up-regulation of mesenchymal markers
(vimentin and N-cadherin) as that of TGF-β. In summary, these dataigration and invasion in RCC cells. (A) Mb-IL-15 expression in human
247-PE, blue peaks). Isotype-matched antibody IgG1 was used as
ls was immunoprecipitated with anti–IL-15 goat antibody L-20 and
pecific band was detected, whereas the isotype control (goat IgG)
r treatment with or without s-IL-15Rα (100 ng/ml) for 4 days. Data
l. Scale bar, 20 μm.
Figure 2. Stimulation of tmb-IL-15 with s-IL-15Rα triggered EMT in RCC cells.786-O cells were stimulated with 10 ng/ml TGF-β or 100 ng/ml
s-IL-15Rα for 4 days. Morphology of cells was observed by phase-contrast microscopy (A). The epithelial marker ZO-1 and themesenchymal
markers vimentin and N-cadherin were analyzed by immunofluorescence staining (B) and Western blot (C). Scale bar, 20 μm. Relative band
intensities were shown as mean ± SEM of three different experiments. *P b .05, **P b .01 compared with control.
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in the enhanced migratory ability of RCC in vitro.
Src/PI3K/Akt/GSK-3β/β-Catenin Signaling Cascade Is
Responsible for s-IL-15Rα–Favored EMT
Next, we tried to clarify the signaling cascades that are responsible
for the s-IL-15Rα–favored EMT process. First, we examined thetypical TGF-β targets Smad2 and Smad3. As shown in Figure S1,
s-IL-15Rα treatment did not significantly modify the phosphoryla-
tion levels of Smad2 and Smad3, which may suggest that this pathway
was not involved in this process. At the same time, we found that
under stimulation of s-IL-15Rα (100 ng/ml), phosphorylations of
Src, PI3K, Akt, and GSK-3β were observed to have started from 30
up to 120 minutes (Figure 3A). S-IL-15Rα also dose-dependently
414 The Mechanism of tmb-IL-15-promoted EMT in RCC Yuan et al. Neoplasia Vol. 17, No. 5, 2015promoted phosphorylation of Src and Akt (Figure 3B). Subsequently,
the interaction between Akt and GSK-3β was enhanced after
s-IL-15Rα stimulation, as shown by immunoprecipitation assay.
These data all demonstrated that s-IL-15Rα activated the Src/PI3K/
Akt/GSK-3β signaling cascade. As we know, the EMT process starts
with the disruption of cell-cell adherent junctions and destabilization
of cadherin-catenin complex. Subsequently, the release of β-catenin
from E-cadherin favors nuclear translocation of β-catenin and renders
it available for transcriptional regulation [20]. This latter step is under
the control of Src/PI3K/Akt/GSK-3β signal cascade [21]. Immuno-
fluorescence analysis shows that β-catenin was localized in cell-cell
adherent junctions, while s-IL-15Rα treatment induces the nuclearFigure 3. S-IL-15Rα stimulated Src/PI3K/Akt signaling pathway and β-c
with 100 ng/ml s-IL-15Rα for the indicated time or with increasing co
p-Src, p-PI3K, p-GSK-3β, and p-Akt were examined by Western blot.
were shown as mean ± SEM of three different experiments. *P b .05,
without s-IL-15Rα (100 ng/ml) for 1 hour. GSK-3β and Akt interactio
negative control. (D) 786-O cells were treated with or without s-IL-1
β-catenin was examined by immunofluorescence staining. Scale barlocalization of β-catenin (Figure 3D). To further confirm the
relationship between the Src/PI3K/Akt/GSK-3β/β-catenin signal
cascade and RCC EMT favored by s-IL-15Rα, Src inhibitor PP2,
PI3K inhibitor LY4294002, and Akt inhibitorMK2206were employed
(Figures S2 and S3). As expected, Src inhibitor PP2 decreased Src and
Akt phosphorylation, suggesting that Akt is the downstream of Src
(Figure 4C). PI3K inhibitor LY4294002 treatment significantly
inhibited s-IL-15Rα–triggered β-catenin nuclear translocation (Figure 4,
A and B) and migration of RCC (Figure 4E). At the same time, Akt
inhibitorMK2206 blocked tmb-IL-15–mediated down-regulation of the
epithelial marker E-cadherin and up-regulation of the mesenchymal
marker vimentin (Figure 4D) and finally reduced the migration of RCCatenin nuclei translocation in RCC cells. (A) 786-O cells were treated
ncentrations (1-500 ng/ml) for 30 minutes (B). The expressions of
GAPDH serves as the loading control, and relative band intensities
**P b .01 versus control group. (C) 786-O cells were treated with or
n was detected by immunoprecipitation. IgG was performed as a
5Rα (100 ng/ml) for 6 hours. After fixation, the cellular location of
, 20 μm.
Figure 4. Src/PI3K/Akt/β-catenin activation was responsible for s-IL-15Rα–induced EMT and metastasis of RCC cells. 786-O cells were
pretreated with or without 10 μM PI3K LY4294002 for 1 hour, followed by stimulation with s-IL-15Rα (100 ng/ml) for 6 hours. Cellular
location of β-catenin was examined by immunofluorescence staining (A) and Western blot (B). Scale bar, 20 μm. (C) 786-O cells were
pretreated with or without 10 μM SRC inhibitor PP2 for 1 hour, followed by stimulation with s-IL-15Rα (100 ng/ml) for 30 minutes.
Phosphorylation and protein levels of Src and Akt in total cell lysate were detected by Western blot. (D and E) 786-O cells were treated
with or without PI3K inhibitor LY4294002 (10 μM) or AKT inhibitor MK2206 (2 μM) accompanied by s-IL-15Ra (100 ng/ml) for 4 days. EMT,
migration, and invasion of cells were examined.
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between tmb-IL-15 and Src/PI3K/Akt/GSK-3β/β-catenin signaling in
EMT of RCC.
Src-Dependent FAK Phosphorylation Contributed to s-IL-
15Rα–Promoted Migration and Invasion of RCC
In cancer cells, Src activation plays a major role not only favoring
EMT process through the Src/Akt signal but may also promoting
cellular migration and invasion through the Src/FAK pathway [22].
These latter activities are triggered by the engagement of integrins with
extracellular matrix proteins, which cause the activation of the Src/FAK
signal [23]. In Figure 5A, stimulation of RCC tmb-IL-15 with the
s-IL-15Rα chain strongly enhances FAK phosphorylation, while Src
inhibitor PP2 can significantly inhibit FAK phosphorylation. To find
out whether s-IL-15Rα–promoted cell migration was associated withFigure 5. FAK signaling accounted for s-IL-15Rα–promoted RCC migr
10 μM Src inhibitor PP2 for 1 hour, followed by stimulation with/
expressions were examined by Western blot. (B) 786-O cells transfec
(100 ng/ml). The expressions of FAK and p-Src were detected by W
transfected with si-FAK or si-NC after treatment with or without s-IL-1
SEM of five fields. *P b .05 compared with control. Scale bar, 20 μmSrc-FAK signaling, FAK-specific siRNA (si-FAK) and negative control
siRNA (si-NC) were transfected into 786-O cells. We observed that
si-FAK but not si-NC inhibits FAK expression and Src phosphorylation
in the cells stimulated with s-IL-15Rα is not affected because it is the
upstream of FAK (Figure 5B).We then further explored the influence of
FAK in the regulation of cell mobility: si-FAK strongly inhibited both
migratory and invasive activities of 786-O cells treated for 4 days with
s-IL-15Rα chain (Figure 5C). These data suggested that Src-dependent
FAK phosphorylation contributed to s-IL-15Rα–promoted migration
and invasion of RCC.
Src-Dependent Erk1/2 Phosphorylation Was Involved in s-IL-
15Rα–Promoted Migration and Invasion of RCC
In Figure 6, A and B, Western blot analysis shows that s-IL-15Rα
dose and time-dependently promoted Erk1/2 phosphorylation, whileation and invasion. (A) 786-O cells were pretreated with or without
without s-IL-15Rα (100 ng/ml) for 30 minutes; p-SRC and p-FAK
ted with si-FAK or si-NC were stimulated with or without s-IL-15Rα
estern blot. (C) The number of invasive cells and migrated cells
5 Rα (100 ng/ml) for 4 days was quantified. Data represent mean ±
.
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which confirmed that s-IL-15Rα–induced Erk1/2 phosphorylation
depends on Src. Further, we found out that Erk1/2 inhibitor
PD98059 can block tmb-IL-15–promoted migration of RCC
(Figure 6E) but has no influence on tmb-IL-15–mediated down-
regulation of the epithelial marker E-cadherin and up-regulation of
the mesenchymal marker vimentin (Figure 6D). These results showFigure 6. Erk1/2 signaling was involved in s-IL-15Rα–promoted RCC m
s-IL-15Rα for the indicated time or with increasing concentrations (1-5
were examined by Western blot. (C) 786-O cells were pretreated w
stimulation with/without s-IL-15Rα (100 ng/ml) for 30 minutes; p-Er
786-O cells were pretreated with or without Erk1/2 inhibitor PD98059
(100 ng/ml) for 30 minutes; p-Erk1/2, Erk1/2, E-cadherin, vimentin, Sna
band densities were calculated and shown as mean ± SEM of three d
786-O cells were treated with or without Erk1/2 inhibitor PD98059 (2
and invasion of cells were examined. Scale bar, 20 μm.that the Src/Erk1/2 pathway may not be involved in the EMT process
but contribute to RCC migration and invasion favored by tmb-IL-15
with its soluble-specific ligand.
Discussion
IL-15 is a cytokine displaying pleiotropic immune-enhancing
activities, as it stimulates natural killer (NK), T and natural killer Tigration and invasion. (A) 786-O cells were treated with 100 ng/ml
00 ng/ml) for 30minutes (B). The expressions of p-Erk1/2 and Erk1/2
ith or without 10 μM Src inhibitor PP2 for 1 hour, followed by
k1/2 and Erk1/2 expressions were examined by Western blot. (D)
(10 μM) for 1 hour, followed by stimulation with/without s-IL-15Rα
il, and Zeb-1 expressions were examined by Western blot. Relative
ifferent experiments. *P b .05, **P b .01 versus control group (F). (E)
0 μM) accompanied by s-IL-15Ra (100 ng/ml) for 4 days. Migration
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properties, IL-15 is regarded as a good candidate for cancer
immunotherapy [11]. This possibility is reinforced by its low toxicity
and efficacy in preclinical tumor models [24]. In this context, IL-15 has
been recently proposed in clinical trials for the treatment of kidney
cancer (NCT01021059 Protocol). However, it is important to be aware
of the potential side effects of IL-15 that plays a major regulatory role in
renal physiopathology. Indeed, renal cancer cells do not secrete IL-15,
do not express IL-15Rγ, and express a tmb-IL-15 [18,19], while renal
cancer stem cells express, as normal tubular cells, the three subunits of
the IL-15R, creating a complex intratumoral interplay where IL-15
could favor (RCC cells) or inhibit cancer stem cells (CSC) tumor
progression [8]. Therefore, much more attention should be paid to
when using IL-15 in renal tumor therapy.
Herein, we confirmed that human RCC express an unusual
transmembrane IL-15 isoform of 27 kDa. Its stimulation with the
s-IL-15Rα chain triggered a complex reverse signal leading to the
development of EMT and the acquisition of increased migratory and
invasive properties, clearly contributing to cancer progression.
Mb-IL-15 exists under two different isoforms: The former is
anchored at the cell membrane through the IL-15Rα chain and
activates surrounding cells expressing the IL-15R through juxtacrine
loops (transpresentation) [14,15], whereas the latter one (tm- IL-15
isoform) is anchored through an IL-15R–independent mechanism
competent not only for transpresentation to opposing cells but also
for the activation of a reverse signal in response to its soluble ligand
s-IL-15Rα (Figure 7) [16,17].
Tmb-IL-15–induced EMT in RCC cells is documented by the loss
of epithelial markers (E-cadherin, ZO-1), the acquisition of mesen-
chymal ones (vimentin and N-cadherin), and the nuclear translocationFigure 7. Illustration for the mechanism underlying s-IL-15Rα–induce
binds to tmb-IL-15 in RCC, Src-dependent PI3K/Akt/GSK-3β/β-catenin
Src-FAK and Src-Erk1/2 signaling are also triggered by s-IL-15Rα/tmb
invasion properties of RCC.of β-catenin. E-cadherin is considered as a tumor suppressor gene [25]
and its down-regulation is a critical event in tumor invasion and a
“master” programmer of EMT. Indeed, disruption of E-cadherin/
β-catenin complexes leads to the loss of epithelial polarization and
allows nuclear translocation of β-catenin. This multifunctional protein
in normal tissues maintains with E-cadherin integrity and polarization
of epithelia, while its aberrant nuclear expression can induce malignant
pathways in normal cells and, through its abnormal activity, behaves as
an oncogene and modulates transcription of genes competent to drive
cancer initiation, progression, survival, and relapse [26].
Several factors have been suggested as potential initiators of renal
EMT. TGF-β is also abundantly produced in the intratumoral RCC
environment where it is likely involved in the induction of the
neoplastic EMT [27,28]. With a few key exceptions, EMT induction
depends on TGF-β and its downstream mediators, including
SMADs. Our data show that RCC stimulation with s-IL-15Rα
induces EMT, triggering events similar to those induced by TGF-β,
but independently on SMAD activation, showing the existence of an
alternative EMT program controlled by tmb-IL-15/s-IL-15Rα
interplay totally independent from TGF-β signaling.
The tmb-IL-15–induced reverse signal involves first of all the
activation of the tyrosine kinase Src, which in turn induces the
phosphorylation of the Akt and Erk1/2 pathways. Both signals may
favor EMT [29]. However, the use of specific inhibitors clearly shows
that in RCC cells stimulated with s-IL-15Rα, only the Akt pathway is
involved in the induction of EMT. Subsequently, Akt phosphory-
lation is associated to a cascade of signals leading to the activation of
PI3K/Akt pathway and/or the phosphorylation of GSK-3β and finally
to the nuclear translocation of β-catenin. The reverse signal induced
by tmb-IL-15 causes in addition the phosphorylation of the FAK thatd EMT, migration, and invasion of human RCCs. When s-IL-15Rα
pathway is activated and responsible for EMT induction. However,
-IL-15 interaction and involved in s-IL-15Rα–induced migration and
Neoplasia Vol. 17, No. 5, 2015 The Mechanism of tmb-IL-15-promoted EMT in RCC Yuan et al. 419is associated to the acquisition of increased migratory and invasive
properties by RCC cells.
In conclusion, the results of this study clarify the signaling pathway
triggered by s-IL-15Rα with tmb-IL-15 and its role during EMT and
migration process of RCC. The detection in RCC of a novel
tmb-IL-15–dependent program controlling EMT activation and the
careful dissection of the reverse signals involved could help to develop
novel targeted therapies for a more efficient treatment of RCC. Indeed,
one could consider the intratumoral silencing of the tmb-IL-15 and of
its ligand that is probably presented to tmb-IL-15 as a soluble molecule
cleaved by ADAM metalloproteases [7,30] or alternatively transported
as a functional molecule by exosomes [31] or transpresented by
bystander cells [32]. These alternatives could offer different levels of
intervention for interfering in the activation of the reverse signal.
However, silencing of the IL-15Rα could be dangerous because its loss
causes severe impairment of NK, NKT, CD8, and intraepithelial
lymphocyte (IEL) lymphocyte homeostasis [33], and it is therefore
mandatory to develop alternative strategies. Actually, specific inhibitors
for Src, Akt, PI3K, GSK-3β, and FAK have been developed [34–37],
and some of them are currently proposed in clinical trials for RCC
combination therapy. It is promising that they may represent potential
therapeutic targets for renal cancer metastasis in the near future.
Appendix A. Supplementary Materials
Supplementary data to this article can be found online at http://dx.doi.
org/10.1016/j.neo.2015.04.002.
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